---
schema_version: "secwatch.filing_event.v1"
accession: "0001564590-22-037625"
form_type: "8-K"
ticker: "ACHV"
cik: "0000949858"
company_name: "ACHIEVE LIFE SCIENCES, INC."
filed_at: "2022-11-14T23:59:59+00:00"
generated_at: "2026-06-21T22:00:08.773762+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Achieve Life Sciences Q3 net loss $13.1M; Phase 3 ORCA-3 and Phase 2 ORCA-V1 enrollment completed

## Summary
- Net loss of $13.1M for Q3 2022; operating expenses $12.6M; cash and restricted cash $18.2M as of Sept 30, 2022.
- Phase 3 ORCA-3 trial of cytisinicline enrolled 750 adult smokers; topline data expected Q2 2023.
- Phase 2 ORCA-V1 trial of cytisinicline in 150 e-cigarette users completed enrollment early; topline data expected Q2 2023.
- Sopharma completed new API purification suite for cytisinicline with >€3M cost, expanding global production capacity.
- 9,710,747 shares outstanding as of Nov 10, 2022; no revenue (pre-commercial stage).

## SEC filing metadata
- accession: 0001564590-22-037625
- form_type: 8-K
- ticker: ACHV
- cik: 0000949858
- company_name: ACHIEVE LIFE SCIENCES, INC.
- filed_at: 2022-11-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/949858/000156459022037625/0001564590-22-037625-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/949858/000156459022037625/achv-8k_20221114.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001564590-22-037625
- JSON: https://secwatch.observer/filing/0001564590-22-037625.json
- Plain text: https://secwatch.observer/filing/0001564590-22-037625.txt

## Key facts
- Earnings Releases
  ACHIEVE LIFE SCIENCES, INC. reported the third quarter ended September 30, 2022 results: net income $13.1 million.
  - Period: the third quarter ended September 30, 2022
  - Net income: $13.1 million
  - Result: reported results
  source text: Total net loss for the three and nine months ended September 30, 2022 was $13.1 million and $31.1 million, respectively.
  evidence_url: https://www.sec.gov/Archives/edgar/data/949858/000156459022037625/0001564590-22-037625-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.